Positron Emission Tomography Market Projected to Reach USD 4.69 Billion by 2032 – SNS Insider
The Positron Emission Tomography (PET) Market Growth Is Driven by Technological Innovations and An Increasing Incidence of Chronic Diseases.
Pune, Feb. 19, 2025 (GLOBE NEWSWIRE) — Global Positron Emission Tomography Market Size & Growth Analysis:
“According to SNS Insider, The Positron Emission Tomography Market size is projected to grow from USD 2.63 billion in 2023 to USD 4.69 billion by 2032, at a CAGR of 6.65% during the forecast period 2024-2032.”
This exceptional growth is driven by several factors such as growing adoption of chronic diseases, increasing demand for early diagnosis and accurate diagnostic procedures, and ongoing technological advancements in imaging modalities.
Positron Emission Tomography (PET) is an advanced imaging technology that offers rich information on body metabolic processes and helps in early disease detection and treatment of diseases like cancer, neurological disorders, and cardiovascular disease. The widespread use of hybrid imaging systems like PET/CT and PET/MRI has largely enhanced diagnostic quality and patient outcomes. The spread of chronic diseases, with escalating healthcare expenditure, is also fuelling the market.
Get a Sample Report of Positron Emission Tomography Market@ https://www.snsinsider.com/sample-request/3443
Major Players Analysis Listed in this Report are
- GE Healthcare – Discovery MI PET/CT, Discovery 710 PET/CT
- Siemens Healthineers – Biograph Vision PET/CT, Biograph mCT PET/CT
- Koninklijke Philips N.V. – Ingenuity TF PET/CT, Vereos Digital PET/CT
- Canon Inc. – Aquilion ONE Genesis PET/CT
- Shanghai United Imaging Healthcare Co., Ltd – uMI PET/CT, uEXPLORER PET/CT
- Shimadzu Corporation – Trinias PET/CT
- Positron Corporation – CardioPET, OncoPET
- CellSight Technologies – CellSight PET Systems
- RefleXion – RefleXion X1 PET/CT
- Clarity Pharmaceuticals – SPECT/CT, ClarityPET
- PETsys Electronics SA – PETsys PET Scanners
- Blue Earth Diagnostics Limited – Axumin PET Imaging
- Qubiotech Health Intelligence S.L. – Qubitech PET Solutions
- Advanced Accelerator Applications – NETSPOT PET/CT
- Lilly – Lilly PET Imaging Solutions
- Agfa-Gevaert Group – PET/CT Systems
- CMR Naviscan – PET Scanner, PET/CT Systems
- Neusoft Corporation – Neusoft PET/CT Systems
- Siemens – Biograph Vision PET/CT, Biograph mCT
- Segamicorp – Segami PET/CT Solutions
- ONCOVISION – Oncovision PET/CT Systems
- MedX Holdings, Inc – MedX PET/CT Systems
- Modus Medical Devices Inc. – PET/CT Systems
- Radiology Oncology Systems – PET/CT Imaging Solutions
- TOSHIBA CORPORATION – Aquilion PET/CT, PET/CT Systems
- General Electric Company – Discovery PET/CT, Discovery MI PET/CT
Positron Emission Tomography Market Trends
- PET combined with CT (PET/CT) and MRI (PET/MRI) is increasing diagnostic efficiency and accuracy. Hybrid systems provide superior anatomical and functional imaging, driving adoption in oncology, cardiology, and neurology procedures.
- Due to the rising incidence of neurodegenerative conditions like Alzheimer’s and Parkinson’s disease, PET imaging is increasingly being used for early diagnosis and disease tracking. Advances in brain imaging research further contribute to the growth of the market.
- Greater investments into PET tracer manufacturing are guaranteeing improved radiopharmaceutical accessibility. Firms are increasing the size of PET radiopharmaceutical manufacturing operations to accommodate demand for F-18, Ga-68, and other emerging tracers.
Positron Emission Tomography Market Report Scope
| Report Attributes | Details |
| Market Size in 2023 | US$ 2.63 billion |
| Market Size by 2032 | US$ 4.69 billion |
| CAGR | CAGR of 6.65% From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Key Regional Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East]), Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia Rest of Latin America) |
| Key Growth Drivers | Advancements in Imaging Technology and Rising Disease Prevalence of chronic diseases, particularly cancer and neurological disorders. |
Need any customization research on Positron Emission Tomography Market, Enquire Now@ https://www.snsinsider.com/enquiry/3443
Segmentation Analysis
By Product
In 2023, PET/CT systems dominated the market with a 75% share due to their capacity to combine anatomical and functional imaging, greatly improving diagnostic accuracy. These systems are extensively applied in cancer detection, neurological disorders, and cardiovascular diseases, providing high-resolution imaging and shorter scan times. In the meantime, PET/MRI systems are experiencing tremendous growth because of their enhanced soft-tissue contrast and lower radiation dose, and hence they are extremely useful in neurology and oncology imaging applications. With more healthcare providers turning to advanced imaging solutions, the adoption of PET/MRI will continue to increase, transforming diagnostic precision and patient care even more in the coming years.
By Application
Oncology was the most dominant application area of PET scans in 2023, holding a market share of 57.4%. The reason for its dominance lies in the growing incidence of cancer and the significance of PET imaging for early diagnosis, staging, and treatment planning. PET scans deliver high-resolution metabolic imaging, which allows physicians to identify malignancies at an early stage and observe treatment effects optimally. On the other hand, neurological use accounts for the most rapidly expanding segment driven by the escalating prevalence of diseases like Alzheimer’s and Parkinson’s disease. The need for sophisticated diagnosis equipment in neurology keeps growing, boosting PET’s uptake for brain imaging.
By End User
Hospitals and surgery centers led the PET market in 2023, with a 60% market share because of the extensive use of advanced imaging technologies to enhance diagnostic accuracy and patient care. These centers are favored by high patient traffic, well-furnished infrastructure, and access to the latest PET imaging systems for oncology, cardiology, and neurology procedures. In the meantime, diagnostic and imaging clinics are the most rapidly expanding end-user segment, propelled by the demand for non-invasive diagnostic testing and the growing trend of outpatient treatment. They are investing in PET technology to provide affordable, high-precision imaging solutions, enhancing accessibility for early disease detection.
Key Market Segments
By Product
- PET/CT Systems
- Low Slice Scanners
- Medium Slice Scanners
- High Slice Scanners
- PET/MRI Systems
By Application
- Oncology
- Neurological
- Cardiovascular
- Other
By End User
- Hospital & Surgical Centers
- Diagnostic & Imaging Clinics
- Ambulatory Care Centers
- Other End Users
Regional Outlook
In 2023, North America dominated the Positron Emission Tomography (PET) market because of the advanced healthcare infrastructure, technological advancements, and robust regulatory backing for diagnostic imaging in the region. Increasing demand for oncological diagnostics, coupled with growth in the incidence of chronic diseases, has propelled market growth.
Asia Pacific is likely to have the highest CAGR over the forecast period, driven by increasing healthcare spending, a fast-growing aging population, and rising cancer rates. China, a dominant player in the region, is scaling up its production of radiopharmaceuticals and enhancing access to sophisticated imaging technology. Europe is also seeing consistent growth, fueled by the increasing adoption of hybrid imaging systems and government efforts to upgrade diagnostic capabilities in clinics and hospitals, facilitating the wider use of PET technology.
Recent Developments
- December 2024: Continuum Therapeutics initiated patient dosing in its Phase 1b PET trial of PIPE-791. The trial is designed to measure receptor occupancy of PIPE-791 in the lung and brain in multiple cohorts via a PET tracer for the LPA1 receptor.
- September 2024: The U.S. Food and Drug Administration cleared GE HealthCare’s diagnostic medicine, Flyrcado, to detect coronary artery disease through PET myocardial perfusion imaging. Flyrcado should become available in early 2025 and can provide high-quality images and better diagnostic sensitivity, especially in patients with elevated body mass indices and women.
Buy a Single-User PDF of Positron Emission Tomography Market Analysis & Outlook Report 2024-2032@ https://www.snsinsider.com/checkout/3443
Table of Contents – Major Key Points
1. Introduction
2. Executive Summary
3. Research Methodology
4. Market Dynamics Impact Analysis
5. Statistical Insights and Trends Reporting
6. Competitive Landscape
7. Positron Emission Tomography Market by Product
8. Positron Emission Tomography Market by Application
9. Positron Emission Tomography Market by End User
10. Regional Analysis
11. Company Profiles
12. Use Cases and Best Practices
13. Conclusion
Access Complete Report Details of Positron Emission Tomography Market Analysis & Outlook 2024-2032@ https://www.snsinsider.com/reports/positron-emission-tomography-market-3443
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company’s aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
CONTACT: Contact Us: Jagney Dave - Vice President of Client Engagement Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. IndiaShorts takes no editorial responsibility for the same.